Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE To compare anti-EGFR and anti-VEGF agents in patients with K-RAS wild-type metastatic colorectal cancer (mCRC) with regards to tumor location. 31646798

2020

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE <b>Expert commentary:</b> Fruquintinib was approved for patients with metastatic colorectal cancer (RAS wild type) who have previously received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy and who have received or are not suitable for anti- VEGF therapy and anti- EGFR therapy. 31177854

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE In metastatic colorectal cancer (mCRC) and metastatic renal cell carcinoma (mRCC), vascular endothelial growth factor inhibitor (VEGF-i) therapy is commonly used to improve overall survival. 30459123

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), was used in combination with traditional chemotherapy as the first line treatment for metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC) and advanced ovarian cancer. 31497360

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Therefore, we performed this review to summarize the available data regarding the optimal sequential treatment of anti-EGFR and -VEGF mAb for RAS or KRAS WT mCRC and discuss the potential mechanisms that may explain this phenomenon. 30863179

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Strong VEGFA staining was present in half of the cases (n=36, 54% of all 67 mCRC cases). 30952738

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Bevacizumab, widely used in patients with metastatic colorectal cancer (CRC), binds both VEGFA and VEGFAxxxb isoforms. 31402291

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Our objective was to evaluate the association between early AEs and survival outcomes for patients treated with ramucirumab, an antibody targeting the VEGF receptor-2 (VEGFR-2), plus FOLFIRI for metastatic colorectal cancer (mCRC). 31676953

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Patients with metastatic colorectal cancer (mCRC) who fail treatment with standard therapies, including chemotherapy and monoclonal antibodies targeting vascular endothelial growth factor or epidermal growth factor receptor, have few treatment options. 30190299

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Vascular endothelial growth factor (VEGF) inhibition by the addition of bevacizumab to the chemotherapy regimen of metastatic colorectal cancer leads to an improved outcome. 31394786

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer. 30377339

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 AlteredExpression BEFREE Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. 30411783

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The standard first-line regimen for mCRC is a combination of chemotherapy plus a biological agent either targeting the main angiogenic growth factor vascular endothelial growth factor (VEGF) via Bevacizumab or by antibodies targeting the epidermal growth factor receptor (EGRF) via Panitumumab or Cetuximab. 31270570

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) have demonstrated efficacy with chemotherapy (CT) as second line treatment for metastatic colorectal cancer (mCRC). 31443300

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Primary objectives were to assess associations between (i) excision repair cross-complementing 1 (ERCC1) expression with progression-free survival (PFS), and (ii) plasma VEGF A (VEGF-A) with PFS in patients with previously untreated mCRC receiving mFOLFOX6-BV or FOLFIRI-BV. 30224341

2019

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Survival of patients with metastatic colorectal cancer (m-CRC) has been significantly improved with the introduction of the monoclonal antibodies that have as target the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR). 28183254

2018

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), is approved for treatment of metastatic colorectal cancer, nonsquamous non-small-cell lung cancer, metastatic kidney cancer, and glioblastoma. 29574193

2018

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Expert commentary: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for metastatic colorectal cancer (mCRC). 30019590

2018

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. 29670046

2018

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. 30405103

2018

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients. 29134647

2018

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Patients receiving Bevacizumab, a vascular endothelial growth factor inhibitor used to treat metastatic colorectal cancer, may be at greater risk of complications after colorectal surgery because of impaired healing. 29420426

2018

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. 29228087

2018

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 AlteredExpression BEFREE This study investigated the association of tumour MMR-status and VEGF-1 expression with response to first-line IFL regimen in mCRCs. 30396964

2018

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE To assess the efficacy and safety of fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, in metastatic colorectal cancer (mCRC) patients. 28103904

2017